Regarding the genetic risk haplotype, results from a pilot phase Ib/IIa, double-blind trial confirmed that the SLE immunological response to tofacitinib depends on STAT4 risk allele rs7574865[T]. This evidence concerns the gene STAT4 and systemic lupus erythematosus.